Загрузка...
Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resi...
Сохранить в:
| Опубликовано в: : | Int J Mol Sci |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8199186/ https://ncbi.nlm.nih.gov/pubmed/34206051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22115990 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|